Focus Day
Tuesday, August 29
Reviewing Mechanisms of Resistance
9.00
Reviewing the Intrinsic Mechanisms of Resistance to Cell Therapy
Sid Kerkar, Vice President, R&D, EXUMA Biotechnology
9.30
Roundtable Discussion: Discussing Mechanisms of Resistance & How to Overcome Them
John Rossi, Vice President, Head of, Translational Medicine, CARGO Therapeutics
Renaud Vaillant, Founder & Chief Executive Officer, Alaya.bio
10:30 11:00 - Morning Break
Leveraging Innate Immune Cells to Overcome the Tumor Microenvironment
11:00
Overcoming Resistance & the Tumor Microenvironment with CAR-Macrophage Therapies
Sumiti Jain, Vice President, Head of R&D, Inceptor Bio
11:30
Leveraging NKT Cells to Tackle the Tumor Microenvironment
Jason Damiano, Chief Scientific Officer, Appia Bio
12:00 1:00 - Lunch Break
Developing Next-Generation CAR-T Therapies to Overcome Mechanisms of Resistance
1:00
Strategies to Deliver Best-in-Class Engineered CAR-T Cell Products to Overcome Resistance & Address Barriers to Patient Access
John Rossi, Vice President, Head of Translational Medicine, CARGO Therapeutics
1:30
Targeting Solid Tumors with SMART CAR-T by Overcoming Suppressive Tumor Microenvironment
LJ Shen, Senior Vice President, Head of R&D, Gracell Biotechnologies
2:00
Remodeling CAR-T Cells to Maintain Memory Phenotype, Improve Tumor Control & Overcome the Immunosuppressive TME with CellPryme
Dan Shelly, Vice President, Business Development & Alliances, Prescient Therapeutics
2:30 3:00 - Afternoon Break
Developing Next-Generation TIL Therapies to Overcome Mechanisms Resistance
3:00
Next-Gen TIL: Counteracting the Solid Tumor Microenvironment
Michelle Simpson Abelson, Executive Director, Research, Iovance Biotherapeutics
3:30
Developing Gene-Edited TIL Cell Therapy Products to Revolutionize the Treatment of Solid Tumors
Karrie Wong, Senior Director, Head of Cell Therapy, KSQ Therapeutics
4:00 - End of Focus Day
Diversity, Equity & Inclusion in Cell Therapy Biopharma
4:10
Discussing Diversity at CAR-TCR
Gregory Fiore, Board Member, Eterna Therapeuticso
4.15
Strengthening Clinical Trial Diversity to Understand Efficacy Across Population Groups
Adalynn Harris, President & Chief Executive Officer, Equity Bridge
4.45
Panel Discussion: Fostering Diversity in Cell Therapy Clinical Trials
Adalynn Harris, President & Chief Executive Officer, Equity Bridge
Albeena Nisar, Scientific Officer & Head of Clinical Manufacturing, CAR-T Cell Therapy Center, Tata Memorial Centre
5.30
Welcome Reception
Reunite with old friends and meet new colleagues before the main event begins.
“Good place to connect to the heartbeat and trends of the cell and gene therapy industry. There were a lot of industry leaders, knowledgeable speakers, helpful vendors, and a good focus to the content.”
Stephen Crimlisk, Manager, MSAT, BioNTech, Past Attendee